Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia - The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)

Journal of Human Hypertension

Volumn 30, Issue 1, 2016, Pages 46-52

  Theilade, S ^a   Claggett, B ^b   Hansen, T W ^a   Skali, H ^b   Lewis, E F ^b   Solomon, S D ^b   Parving, H H ^c,d,e   Pfeffer, M ^b   Mcmurray, J J ^f   Rossing, P ^a,d,e  

^a STENO DIABETES CENTER   (Denmark)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c University of Copenhagen   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HEMOGLOBIN A1C; INSULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; ANTIANEMIC AGENT;

ADULT; AGED; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG TREATMENT FAILURE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROGNOSTIC ASSESSMENT; PROTEIN URINE LEVEL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; AGE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANEMIA; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DARBEPOETIN ALFA; DIABETES MELLITUS, TYPE 2; FEMALE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84949113787     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.22     Document Type: Article

References (44)

1. Winston GJ, Palmas W, Lima J, Polak JF, Bertoni AG, Burke G, et al. Pulse pressure, and subclinical cardiovascular disease in the multi-ethnic study of atherosclerosis. Am J Hypertens 2013; 26: 636-642
2. Domanski MJ, Davis BR, Pfeffer MA, Kastantin M, Mitchell GF. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375-380
3. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure, and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401
4. Franklin SS, Gustin W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315
5. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-1249
6. Glynn RJ, Chae CU, Guralnik JM, Taylor JO, Hennekens CH. Pulse pressure, and mortality in older people. Arch Intern Med 2000; 160: 2765-2772
7. Gu YM, Thijs L, Li Y, Asayama K, Boggia J, Hansen TW, et al. Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations. Hypertension 2014; 63: 229-237
8. Schram MT, Kostense PJ, van Dijk RA, Dekker JM, Nijpels G, Bouter LM, et al. Diabetes, pulse pressure, and cardiovascular mortality: the Hoorn Study. J Hypertens 2002; 20: 1743-1751
9. Schram MT, Chaturvedi N, Fuller JH, Stehouwer CD. Pulse pressure is associated with age, and cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. J Hypertens 2003; 21: 2035-2044
10. Kengne AP, Czernichow S, Huxley R, Grobbee D, Woodward M, Neal B, et al. Blood pressure variables, and cardiovascular risk: new findings from ADVANCE. Hypertension 2009; 54: 399-404
11. Liu JH, Chen CC, Wang SM, Chou CY, Liu YL, Kuo HL, et al. Association between pulse pressure, and 30-month all-cause mortality in peritoneal dialysis patients. Am J Hypertens 2008; 21: 1318-1323
12. Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis, and a prospective analysis on cardiovascular mortality. Hypertension 1989; 13: 392-400
13. Greenberg J. Antihypertensive treatment alters the predictive strength of pulse pressure, and other blood pressure measures. Am J Hypertens 2005; 18: 1033-1039
14. Petrie CJ, Voors AA, van Veldhuisen DJ. Low pulse pressure is an independent predictor of mortality, and morbidity in non ischaemic, but not in ischaemic advanced heart failure patients. Int J Cardiol 2009; 131: 336-344
15. Petrie CJ, Voors AA, Robertson M, van Veldhuisen DJ, Dargie HJ. A low pulse pressure predicts mortality in subjects with heart failure after an acute myocardial infarction: a post-hoc analysis of the CAPRICORN study. Clin Res Cardiol 2012; 101: 29-35
16. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering, and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762
17. Reboldi G, Angeli F, de Simone G, Staessen JA, Verdecchia P. Tight versus standard blood pressure control in patients with hypertension with, and without cardiovascular disease. Hypertension 2013; 63: 475-482
18. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure, and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771
19. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041
20. UK Prospective Diabetes Study Group Tight blood pressure control, and risk of macrovascular, and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713
21. Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W. Blood pressure, and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care 2011; 34: 34-38
22. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril, and indapamide on macrovascular, and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840
23. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensinconverting enzyme inhibitor beyond blood pressure lowering: beyond blood pressure or beyond the brachial artery? J Hypertens 2005; 23: 551-556
24. Mahmud A, Feely J. Arterial stiffness, and the renin-angiotensinaldosterone system. J Renin Angiotensin Aldosterone Syst 2004; 5: 102-108
25. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure, and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225
26. Theilade S, Lajer M, Persson F, Joergensen C, Rossing P. Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care 2013; 36: 715-721
27. Gordin D, Waden J, Forsblom C, Thorn LM, Rosengard-Barlund M, Heikkila O, et al. Arterial stiffness, and vascular complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. Ann Med 2012; 44: 196-204
28. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes, and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
29. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
30. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, et al. Association between cardiac biomarkers, and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 2011; 58: 717-728
31. McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, et al. Predictors of fatal, and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am Heart J 2011; 162: 748-755
32. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999; 100: 354-360
33. Khattar RS, Swales JD, Dore C, Senior R, Lahiri A. Effect of aging on the prognostic significance of ambulatory systolic, diastolic, and pulse pressure in essential hypertension. Circulation 2001; 104: 783-789
34. Theilade S, Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Arterial stiffness, and endothelial dysfunction independently, and synergistically predict cardiovascular, and renal outcome in patients with type 1 diabetes. Diabet Med 2012; 29: 990-994
35. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure, and cardiovascular mortality in normotensive, and hypertensive subjects. Hypertension 1998; 32: 560-564
36. Asmar R, Vol S, Brisac AM, Tichet J, Topouchian J. Reference values for clinic pulse pressure in a nonselected population. Am J Hypertens 2001; 14: 415-418
37. Borghi C, Dormi A, Ambrosioni E, Gaddi A. Relative role of systolic, diastolic, and pulse pressure as risk factors for cardiovascular events in the Brisighella Heart Study. J Hypertens 2002; 20: 1737-1742
38. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity, and its relationship to mortality in diabetes, and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085-2090
39. Smith A, Karalliedde J, De AL, Goldsmith D, Viberti G. Aortic pulse wave velocity, and albuminuria in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1069-1075
40. Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, et al. Pulse pressure, and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002; 287: 2677-2683
41. Miura K, Dyer AR, Greenland P, Daviglus ML, Hill M, Liu K, et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular, and all-cause mortality rates: The Chicago Heart Association Detection Project in Industry Study. Hypertension 2001; 38: 232-237
42. Pannier BM, Guerin AP, Marchais SJ, London GM. Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition, and beta-blocker in essential hypertension. Clin Exp Pharmacol Physiol 2001; 28: 1074-1077
43. Nakamura T, Fujii S, Hoshino J, Saito Y, Mizuno H, Saito Y, et al. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28: 937-943
44. Boutouyrie P, Beaussier H, Achouba A, Laurent S. Destiffening effect of valsartan, and atenolol: influence of heart rate, and blood pressure. J Hypertens 2014; 32: 108-114